Mike Bentivegna is currently Vice President, Commercial Development and Lifecycle Innovation, Zoetis Inc. He leads a group responsible for collaborating with R&D and the Commercial organization in establishing species innovation strategies, driving value in Zoetis’ R&D portfolio, and preparing new products for launch. Mike is a twenty-nine year veteran of Pfizer/Zoetis. He joined Animal Health in late 2010 as head of U.S. Companion Animal Marketing, where he served for five years, contributing to the business units success and elevating the skill set of its marketers. Zoetis was spun off from Pfizer in an IPO in 2013.
Mike previously spent thirteen years in Pfizer Human Health Marketing in senior marketing positions on major brands and therapeutic areas like Zyrtec, Zyvox, Spiriva, Eliquis, Pain and Inflammation (Celebrex), Cardiovascular (Lipitor/Caduet) in both U.S. Marketing and Global Commercial Development positions. Prior to human health, Mike spent his first ten years in Pfizer’s OTC division working on all of Pfizer’s leading OTC medicines and was the named the first global team leader for the division, responsible for the Eye Care TA and global strategy for the Visine franchise.
Mike is graduate of Fairfield University with a BS in Marketing and where he was elected Student Government President his senior year. He holds an MBA from the Sawyer School of Management at Suffolk University, where he received a full tuition graduate assistantship.
Mikes’ volunteer and support activities include Wakeman Boys and Girls Club, Operation Hope and Fairfield University where he was a past member of the Alumni Board of Directors and is currently is a mentor to ten Creative Life Sophomore Residential College students. He has been a member of the President’s Circle for over twenty years.
Mike lives in Southport, Connecticut with his wife Wendy and feline family members Ritz and Pippin. He has two adult children, Kevin and Brittney.
s the Vice President of Commercial Strategy & Business Development at Zafgen, Erin is a senior member of the core management team with responsibility for New Product Planning, Portfolio Management, Corporate Strategy and Business Development. Zafgen is a clinical-stage biopharmaceutical company developing novel therapies for patients affected by a range of metabolic diseases.
Prior to joining Zafgen, Erin was an executive at GlaxoSmithKline where she held several VP roles in the Pharmaceuticals business and led global teams in Marketing, Business Development and R&D Strategy. Over her 25-year career in the Pharmaceutical Industry, Erin held several roles of increasing responsibility in Sales, Marketing, New Product Planning, Business Development and R&D, which allowed her to gain significant experience in the complex tradeoffs and decision-making that goes into the discovery, development and commercialization of new medicines.
Career highlights for Erin include: leading the Alliance Management team that was recognized globally in the BCG Survey; contributing to the in-licensing of several high value assets; successfully launching a new medicine in the US, where Erin was selected as one of the ‘Top Marketing 100’ by Advertising Age magazine; and being named a ‘Rising Star’ by the Healthcare Businesswomen’s Association. Erin is known for her high-energy, ability to build meaningful and lasting professional relationships, and her authentic leadership style. Erin was part of the team that initiated the Women’s Leadership Initiative at GlaxoSmithKline. She actively mentors both men and women in the Industry at all stages in their careers. Erin currently serves on the Board of Life Sciences PA and has previously served on Boards of other non-profit organizations focused on patient advocacy and finance.
Erin is a graduate of Franklin & Marshall College. She also completed the Transformational Executive Program associated with the Wharton Executive Education Program at the University of Pennsylvania. She holds a certification in coaching from the Association for Professional Executive Coaching & Supervision, and a Certificate of Achievement in Alliance Management from the Association of Strategic Alliance Professionals. Erin and her family live in the Greater Philadelphia area and are lifelong, admittedly sometimes suffering, supporters of the Philadelphia sports teams.
Paul oversees our business activities in North America. Since completing his PhD in chemistry at Stony Brook University, he has spent more than 20 years providing guidance and support to the healthcare industry. He has held leadership roles at various consulting firms that engage with biopharmaceutical and medical technology companies in nearly all functional areas, including sales, marketing, medical affairs, business development and supply chain. Paul’s focus at Prescient is helping our clients achieve and sustain peak commercialization targets across a wide range of therapy areas.
Tony Russell is currently the Senior Director, Product Strategy and Commercial Planning on Theravance Biopharma with a primary focus on new product planning for respiratory and dermatology. Tony’s prior therapeutic area experiences include pain, oncology, rare diseases, anemia, and nephrology.
Over the course of Tony’s nearly 20-year career, he has established a unique blend of skills and therapeutic area knowledge providing valuable perspectives and insights for the development and commercialization of biologic and small molecule therapeutics. Tony has successfully utilized these experiences in developing commercialization strategies and evaluations for new drug candidates as well as in the market conditioning and launching of new therapeutics.
Katja Wachtendonk is a Global New Products Director at Novartis Pharma. In her role, Katja is responsible to establish Novartis Global Cardio-renal & Metabolic Disease Area- and Program Strategies for compounds in Ph-I to early Ph-III in close collaboration with R&D. Katja leads and aligns portfolio strategies to maximize the value of assets and execute against short- and long-range franchise goals, provides commercial expertise to support BD&L, identifies transformational strategies (biomarker, diagnostics, etc) and innovates by leveraging technology-enabled solutions to improve patient outcomes.
Prior to that role, Katja spent more than a decade in global and local marketing leadership roles on Merck and Novartis blockbuster products SINGULAIR, COZAAR, ULTIBRO, QVM149, QAW039 from early Ph-III through launch and LoE in the U.S., Germany and Japan, and supported the companies’ business in Europe, AMAC and LACAN.
Katja holds a Pharm.D. from the Freie Universitaet Berlin (Germany).